Patents Assigned to SDG, Inc.
  • Publication number: 20230172868
    Abstract: The invention provides an improved lipid-based nanoparticle, which can be used to deliver a therapeutic agent to a subject, such as but not limited to a mammal, such as but not limited to a human. In certain embodiments, the nanoparticle of the invention has reduced aggregation properties as compared to those taught in the prior art.
    Type: Application
    Filed: February 1, 2023
    Publication date: June 8, 2023
    Applicant: SDG, Inc.
    Inventor: W. Blair Geho
  • Patent number: 11517529
    Abstract: The present invention is embodied by a composition capable of chaperoning a typically non-orally available therapeutic or diagnostic agent through the environment of the digestive tract such that the therapeutic or diagnostic agent is bioavailable. The composition may or may not be targeted to specific cellular receptors, such as hepatocytes. Therapeutic agents include, but are not limited to, insulin, calcitonin, serotonin, and other proteins. Targeting is accomplished with biotin or metal based targeting agents.
    Type: Grant
    Filed: January 30, 2020
    Date of Patent: December 6, 2022
    Assignee: SDG, Inc.
    Inventors: John R. Lau, W. Blair Geho
  • Patent number: 11077173
    Abstract: The invention provides an improved lipid-based nanoparticle, which can be used to deliver a therapeutic agent to a subject, such as but not limited to a mammal, such as but not limited to a human. In certain embodiments, the nanoparticle of the invention has reduced aggregation properties as compared to those taught in the prior art.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: August 3, 2021
    Assignee: SDG, Inc.
    Inventor: W. Blair Geho
  • Patent number: 11071715
    Abstract: The invention provides an improved lipid-based nanoparticle, which can be used to deliver a therapeutic agent to a subject, such as but not limited to a mammal, such as but not limited to a human. In certain embodiments, the nanoparticle of the invention has reduced aggregation properties as compared to those taught in the prior art.
    Type: Grant
    Filed: September 6, 2019
    Date of Patent: July 27, 2021
    Assignee: SDG, Inc.
    Inventor: W. Blair Geho
  • Patent number: 10918700
    Abstract: The invention provides methods of treating a subject having diabetes mellitus and/or a metabolic derangement.
    Type: Grant
    Filed: April 10, 2020
    Date of Patent: February 16, 2021
    Assignee: SDG, Inc.
    Inventor: W. Blair Geho
  • Publication number: 20200323961
    Abstract: The invention provides methods of treating a subject having diabetes mellitus and/or a metabolic derangement.
    Type: Application
    Filed: April 10, 2020
    Publication date: October 15, 2020
    Applicant: SDG, Inc.
    Inventor: W. Blair Geho
  • Patent number: 10751418
    Abstract: The present invention is embodied by a composition capable of chaperoning a typically non-orally available therapeutic or diagnostic agent through the environment of the digestive tract such that the therapeutic or diagnostic agent is bioavailable. The composition may or may not be targeted to specific cellular receptors, such as hepatocytes. Therapeutic agents include, but are not limited to, insulin, calcitonin, serotonin, and other proteins. Targeting is accomplished with biotin or metal based targeting agents.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: August 25, 2020
    Assignee: SDG, Inc.
    Inventors: W. Blair Geho, John R. Lau
  • Patent number: 10568835
    Abstract: The present invention is embodied by a composition capable of chaperoning a typically non-orally available therapeutic or diagnostic agent through the environment of the digestive tract such that the therapeutic or diagnostic agent is bioavailable. The composition may or may not be targeted to specific cellular receptors, such as hepatocytes. Therapeutic agents include, but are not limited to, insulin, calcitonin, serotonin, and other proteins. Targeting is accomplished with biotin or metal based targeting agents.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: February 25, 2020
    Assignee: SDG, Inc.
    Inventors: John R. Lau, W. Blair Geho
  • Patent number: 10463616
    Abstract: The instant invention is drawn to a hepatocyte targeted composition comprising insulin associated with a lipid construct comprising an amphipathic lipid and an extended amphipathic lipid that targets the construct to a receptor displayed by an hepatocyte. The composition can comprise a mixture of free insulin and insulin associated with the complex. The composition can be modified to protect insulin and the complex from degradation. The invention also includes methods for the manufacture of the composition and loading insulin into the composition and recycling various components of the composition. Methods of treating individuals inflicted with diabetes.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: November 5, 2019
    Assignee: SDG, Inc.
    Inventors: John R. Lau, W. Blair Geho
  • Patent number: 10004686
    Abstract: The instant invention is drawn to a hepatocyte targeted composition comprising insulin associated with a lipid construct comprising an amphipathic lipid and an extended amphipathic lipid that targets the construct to a receptor displayed by an hepatocyte. The composition can comprise a mixture of free insulin and insulin associated with the complex. The composition can be modified to protect insulin and the complex from degradation. The invention also includes methods for the manufacture of the composition and loading insulin into the composition and recycling various components of the composition. Methods of treating individuals inflicted with diabetes.
    Type: Grant
    Filed: June 12, 2013
    Date of Patent: June 26, 2018
    Assignee: SDG, Inc.
    Inventors: John R. Lau, W. Blair Geho
  • Patent number: 9943602
    Abstract: The present invention is embodied by a composition capable inducing weight loss in a patient in need thereof.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: April 17, 2018
    Assignee: SDG, Inc.
    Inventors: W. Blair Geho, John R. Lau
  • Patent number: 9145453
    Abstract: The present invention is embodied by a composition capable inducing weight loss in a patient in need thereof.
    Type: Grant
    Filed: March 26, 2010
    Date of Patent: September 29, 2015
    Assignee: SDG, Inc.
    Inventors: W. Blair Geho, John R. Lau
  • Patent number: 9034372
    Abstract: The instant invention is drawn to a hepatocyte targeted composition comprising insulin associated with a lipid construct comprising an amphipathic lipid and an extended amphipathic lipid that targets the construct to a receptor displayed by an hepatocyte. The composition can comprise a mixture of free insulin and insulin associated with the complex. The composition can be modified to protect insulin and the complex from degradation. The invention also includes methods for the manufacture of the composition and loading insulin into the composition and recycling various components of the composition. Methods of treating individuals inflicted with diabetes.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: May 19, 2015
    Assignee: SDG, Inc.
    Inventors: John R. Lau, W. Blair Geho
  • Patent number: 8962015
    Abstract: The present invention is embodied by a composition capable of chaperoning a typically non-orally available therapeutic or diagnostic agent through the environment of the digestive tract such that the therapeutic or diagnostic agent is bioavailable. The composition may or may not be targeted to specific cellular receptors, such as hepatocytes. Therapeutic agents include, but are not limited to, insulin, calcitonin, serotonin, and other proteins. Targeting is accomplished with biotin or metal based targeting agents.
    Type: Grant
    Filed: September 28, 2007
    Date of Patent: February 24, 2015
    Assignee: SDG, Inc.
    Inventors: John R. Lau, W. Blair Geho
  • Patent number: 8846053
    Abstract: The present invention is embodied by a composition capable inducing weight loss in a patient in need thereof.
    Type: Grant
    Filed: June 15, 2010
    Date of Patent: September 30, 2014
    Assignee: SDG, Inc.
    Inventors: W. Blair Geho, John R. Lau
  • Publication number: 20140243430
    Abstract: The present invention is embodied by a composition capable inducing weight loss in a patient in need thereof.
    Type: Application
    Filed: May 2, 2014
    Publication date: August 28, 2014
    Applicant: SDG, INC.
    Inventors: W. BLAIR GEHO, JOHN R. LAU
  • Publication number: 20130183270
    Abstract: The present invention is embodied by a composition capable of chaperoning a typically non-orally available therapeutic or diagnostic agent through the environment of the digestive tract such that the therapetuic or diagnostic agent is bioavailable. The composition may or may not be targeted to specific cellular receptors, such as hepatocytes. Therapeutic agents include, but are not limited to, insulin, calcitonin, serotonin, and other proteins. Targeting is accomplished with biotin or metal based targeting agents.
    Type: Application
    Filed: March 5, 2013
    Publication date: July 18, 2013
    Applicant: SDG, Inc.
    Inventor: SDG, Inc.
  • Patent number: 8303983
    Abstract: A metal targeting complex which associates with a charged liposomal structure is provided. The metal targeting complex provides the targetability of the liposomal construct to the desired receptor sites of a warm-blooded host for therapy or diagnostic use.
    Type: Grant
    Filed: January 14, 2010
    Date of Patent: November 6, 2012
    Assignee: SDG, Inc.
    Inventors: John R. Lau, W. Blair Geho, George H. Snedeker
  • Patent number: 8257735
    Abstract: The instant invention is drawn to a hepatocyte targeted composition comprising a mixture of free recombinant human insulin isophane and free Recombinant human regular insulin insulin and a mixture of recombinant human insulin isophane and Recombinant human regular insulin insulin associated with a water insoluble target molecule complex, wherein the complex comprises multiple linked individual units and a supra-molecular lipid construct matrix. Recombinant human insulin isophane and Recombinant human regular insulin insulin are present within the complex in at least one form wherein the recombinant human insulin isophane and Recombinant human regular insulin insulin have regions of positive charge which interacts with a negative charge on the complex. The invention also includes methods for the manufacture of the composition and methods of managing blood glucose levels in individuals with Type I and Type II diabetes.
    Type: Grant
    Filed: November 23, 2010
    Date of Patent: September 4, 2012
    Assignee: SDG, Inc
    Inventors: John R. Lau, W. Blair Geho
  • Publication number: 20110135725
    Abstract: The instant invention is drawn to a hepatocyte targeted composition comprising insulin associated with a lipid construct comprising an amphipathic lipid and an extended amphipathic lipid that targets the construct to a receptor displayed by an hepatocyte. The composition can comprise a mixture of free insulin and insulin associated with the complex. The composition can be modified to protect insulin and the complex from degradation. The invention also includes methods for the manufacture of the composition and loading insulin into the composition and recycling various components of the composition. Methods of treating individuals inflicted with diabetes.
    Type: Application
    Filed: May 16, 2006
    Publication date: June 9, 2011
    Applicant: SDG, Inc.
    Inventors: John R. Lau, W. Blair Geho